Browse by author
Lookup NU author(s): Professor Anthony MoormanORCiD,
Professor Christine Harrison FRCPath FMedSci
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Patients with acute lymphoblastic leukemia (ALL) and an intrachromosomal amplification of chromosome 21 (iAMP21) comprise a novel and distinct biological subgroup. We prospectively screened 1630 (84%) patients treated on the UK MRC ALL97 protocol for iAMP21 and herein present demographic, clinical, and survival data on the 28 (2%) children found to harbor this abnormality. They had a common or pre-B ALL immunophenotype, were significantly older (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with children without this abnormality. Notably, patients with iAMP21 had a significantly inferior event-free and overall survival at 5 years compared with other patients: 29% (95% confidence interval [CI], 13%-48%) versus 78% (95% CI, 76%-80%) and 71% (95% CI, 51%-84%) versus 87% (95% CI, 85%-88%), respectively. As a result of this 3-fold increase in relapse risk, newly diagnosed patients with iAMP21 recruited to the current UK MRC ALL2003 trial are being treated on the high-risk arm and are considered for bone marrow transplantation in first remission.
Author(s): Moorman AV, Richards SM, Robinson HM, Strefford JC, Gibson BES, Kinsey SE, Eden TOB, Vora AJ, Mitchell CD, Harrison CJ
Publication type: Article
Publication status: Published
ISSN (print): 0006-4971
ISSN (electronic): 1528-0020
Notes: UK Medical Research Council (MRC)/National Cancer Research Institute (NCRI) Childhood Leukaemia Working Party (CLWP)
Research Support, Non-U.S. Gov't
Altmetrics provided by Altmetric